Richmond Pharmacologys latest research on the effect of food on the QT interval Presented at the 6th European Congress of Pharmacology 2012

Posted:
1
June 2012

Food alters the QTc and might be an attractive non-pharmacological method of confirming assay sensitivity in Thorough QT (TQT) studies. This idea was recently examined (Taubel et al., 2011) and showed that food shortens QTcF. This is important because previously it has been debated in the literature to whether euglycaemic hyperinsulinemia can prolong the QTc interval (Gastaldelli et al. 2000).The European Congress of Pharmacology will be hosted this year by the Spanish Society of Pharmacology in Granada, Spain from 17-20 July, and will bring together pharmacologists from all over the world to debate current drug research and development issues from �bench to bedside�.Following Dr Taubel�s presentation  at the DIA 3rd Cardiac Safety Workshop in Japan, he will present his latest data assessing how late changes  i.e. 2-4 hours after the end of a euglycaemic insulin clamp can lead to significant increases in QTcF in healthy subjects. The presentation will be based on a single centre, randomised, placebo- and positive-controlled study that was carried out by Richmond Pharmacology in both healthy Caucasian and Japanese subjects. The euglycaemic insulin clamp was used to investigate the effects of insulin, C-peptide and glucose on the QT interval.View the Scientific Program

Latest news

Upcoming Event

The 41st Annual Scientific Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (JSCPT)

4 – 5 December 2020
The 41st Annual Scientific meeting focuses on international collaboration in the pursuit of drug discovery and drug development.
View event

Contributing to our community in 2020

December 17, 2020
Richmond Pharmacology has a long-standing tradition of supporting local, national, and international charities and 2020 is no exception.
Read more

Richmond Pharmacology supports Cardior Pharmaceuticals with the pioneering trial of an oligonucleotide-based drug in heart failure patients

December 14, 2020
Richmond Pharmacology is delighted to welcome the positive Phase Ib results of Cardior Pharmaceuticals lead compound CDR132L for heart failure.
Read more

Marking a milestone for gene editing

November 10, 2020
We are pleased to share that Richmond Pharmacology, in partnership with Intellia Therapeutics and the Royal Free Hospital, have treated the first patient in a landmark CRISPR/Cas9 clinical trial of NTLA-2001
Read more